ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyRiehenYmmunobio AG
Ymmunobio AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Ymmunobio AG is a preclinical biotechnology company developing antibody-based therapies for solid tumors. Its pipeline includes NPTXR-targeted antibody-drug conjugates, radioligand therapies, and bispecific and trispecific T-cell engagers.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

Ymmunobio AG

✓ Offered8
Antibody-based cancer therapies for solid tumors
Antibody-based therapies for solid tumors, focusing on first-in-class programmes against NPTXR and on hard-to-treat tumour types.
Antibody-Drug-Conjugates (ADC)
Dual-payload anti-NPTXR ADCs with a 4+4 linker–payload architecture, designed for precise tumour targeting and cytotoxic payload delivery; programme YB-811 in the preclinical stage.
Radiopharmaceuticals (RPT)
NPTXR-targeted radiopharmaceuticals for imaging and therapy with 177Lu and 161Tb, including RPT-Dx and RPT-Tx; programmes YB-830, YB-831 and YB-832.
Bi-specific T-cell engagers (BiTCE)
Bi-specific T-cell engagers that redirect T cells to NPTXR-positive tumours and enable selective immune-mediated tumour cell killing; programmes YB-820 and YB-821.
Tri-specific T-cell engagers (TriTCE)
Tri-specific T-cell engagers with an aCD3 and aCD28 component for T-cell activation against NPTXR-positive tumours; programme YB-880 in the lead-optimization stage.
CAR-T cell therapy
NPTXR-directed CAR-T cells for tumour-specific recognition and killing in solid tumours, as a later platform expansion with programme YB-840.
Investor information
Presentations, fact sheets and company information for investors, including a non-confidential deck, an investor fact sheet and contact for partnering and milestones.
Contact and company information
Contact form, email contact, company details, and information on the team, advisory board, board of directors, and locations in Basel and Princeton.
Trust & reputation

ranQ Trust Score of Ymmunobio AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 58% · As of November 2026

Ymmunobio AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Ymmunobio AG scores 77.1 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.64.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Ymmunobio AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Ymmunobio AG scores 20.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.31.44%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.10.04%
Qualifications+0.00

Ymmunobio AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

October 16, 2023Media
Industry leaders to take startups to new heights
startupticker.ch

Knowledge

No knowledge articles yet

Once Ymmunobio AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Ymmunobio AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Ymmunobio AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Ymmunobio AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Gartengasse 12
4125 Riehen

At a glance

Legal form
Corporation
UID
CHE-468.419.785
Founded
2021 · 5 years
Last commercial register change
August 24, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SB
    SOTIO Biotech AG
    Basel
    MB
    MabTree Biologics AG
    Basel
    CT
    ClearideBio Therapeutics AG
    Basel
    VA
    Versameb AG
    Basel
    FI
    FatiAbGen International GmbH
    Basel
    AS
    Autolus Switzerland AG
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    CD
    CORETAG Diagnostics AG
    Basel